Associate Scientist II

This role is considered On-Site.

Overview

The successful candidate will be part of the Process Chemistry group, responsible for the process development and in-house non-GMP manufacture of modified oligonucleotides and siRNAs. This role will work closely with both upstream and downstream teams in manufacturing and process development. The candidate must demonstrate the ability to work as a team player in a highly dynamic environment with competing deadlines.

This position is onsite and will be primarily located in Cambridge, MA.

Key Responsibilities

• Support oligonucleotide synthesis method development, optimization and scaling up.
• Support downstream processing method optimization.
• Execution of oligonucleotide synthesis and downstream processes to provide the research and in-house non-GMP material in a tight timeline.
• Execution of in-process analytical tests
• Participate in creating and reviewing SOPs and batch records in support of the in-house non-GMP manufacture.

Qualifications

• BS in Chemistry with a minimum of 2 years lab experience, preferably in an industrial setting.
• Experience in oligonucleotide including phosphoramidite chemistry, chromatography, ultrafiltration, etc.
• Experience in analytical techniques (pH, osmolality, conductivity measurement, HPLC, LC-MS) or related hands-on experience.
• Experience in record-keeping and excellent laboratory documentation practice required.
• Strong commitment to high laboratory and scientific standard; ability to maintain a safe, clean, and orderly laboratory work environment; assist in routine lab and equipment maintenance.
• Good written and oral communication skills.

About Alnylam:Alnylam Pharmaceuticals (Nasdaq: ALNY) has led the translation of RNA interference (RNAi) into a whole new class of innovative medicines with the potential to transform the lives of people afflicted with rare and more prevalent diseases. Based on Nobel Prize-winning science, RNAi therapeutics represent a powerful, clinically validated approach to treating diseases at their genetic source by "interfering" with mRNA that cause or contribute to disease. Since our founding in 2002, Alnylam has led the RNAi Revolution and continues to turn scientific possibility into reality.

Our culture:Our people-first culture is guided by our core values: fiercely innovative, open culture, purposeful urgency, passion for excellence, and commitment to people, and these values influence how we work and the business decisions we make. Thanks to feedback from our employees over the years, we've been fortunate to be named a top employer around the world. Alnylam is extremely proud to have been recognized as the #1 Large Employer by Boston Globe Top Places to Work in 2023 for the third consecutive year, one of Science Magazine's Top Biopharma Employers, one of America's Most Responsible Companies for 2024 by Newsweek, a Fast Company Best Workplace for Innovators, and a Great Place to Work in Canada, France, Italy, Spain, Switzerland, and UK - among others.

At Alnylam, we commit to an inclusive recruitment process and equal employment opportunity. We are dedicated to building an environment where employees can feel that they belong, can bring their authentic selves to work, and achieve to their full potential. By empowering employees to embrace their unique differences at work, our business grows stronger with advanced and original thinking, allowing us to bring groundbreaking medicines to patients. Qualified applicants will receive consideration for employment without regard to their race, color, religion, age, sex, sexual orientation, gender identity or expression, national origin, ethnicity, marital status, protected veteran status, disability, or any other characteristics prohibited by law.